Eikon Therapeutics (EIKN) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Eikon Therapeutics is the larger company by market cap ($404.6 million vs $383.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EIKN | ZURA |
|---|---|---|
| Share price | $7.47 | $4.00 |
| Market cap | $404.61M | $383.32M |
| 1-day change | -0.40% | -3.15% |
| YTD return | — | -23.66% |
| 1-year return | — | -11.31% |
| EPS (TTM) | $-8.51 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.40 | $7.44 |
| 52-week low | $7.02 | $3.15 |
| Distance from 52-week high | -57.07% | -46.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +229.32% | +350.00% |
| Average volume | 497.87K | 1.44M |
| Shares outstanding | 54.17M | 95.83M |
| Employees | 384 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
EIKN vs ZURA FAQ
Which is bigger, Eikon Therapeutics or Zura Bio?
Eikon Therapeutics (EIKN) is larger, with a market capitalization of $404.61M compared with $383.32M for Zura Bio (ZURA).
Are Eikon Therapeutics and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.